Page 254«..1020..253254255256..260270..»

Category Archives: Stem Cells

Stem Cells Help Md. Boy With Cerebral Palsy Walk

Posted: November 9, 2012 at 2:50 am

EASTERN SHORE, Md. (WJZ) The miracle of stem cells changes the life of a little boy from the Eastern Shore.

Adam May has the amazing story of a mother and the choice she made moments after her son was born.

Xander McKinley was a beautiful babybut challenging. The newborn didnt eat or sleep well, and by two-years-old, he couldnt walk or even crawl.

Something just wasnt right, said Xanders mother, Jennifer McKinley.

Jennifer McKinley got the news every parent fears. Xander had cerebral palsya brain condition that slows motor functions.

Adam: Did you ever fear he would never have a normal life? Jennifer: We thought he wasnt going to be able to walk. It was heart-wrenching, that we knew this was permanent.

Turns out, it wasnt permanent. That young boy frustrated by immobility can now stand on his own, and even take a few stepsafter a groundbreaking experimental stem cell transfusion.

Adam: Arent you walking better now? Xander: Yeah. Adam: How good does that feel? Xander: Great!

The six-year-old can finally climb a fence with his brother.

Adam: Youre so fast now Xander: Yeah!

Read the rest here:
Stem Cells Help Md. Boy With Cerebral Palsy Walk

Posted in Stem Cells | Comments Off on Stem Cells Help Md. Boy With Cerebral Palsy Walk

Stem cells and nanofibers stimulating nerve research

Posted: November 9, 2012 at 2:50 am

Every week in his clinic at the University of Michigan, neurologist Joseph Corey, M.D., Ph.D., treats patients whose nerves are dying or shrinking due to disease or injury. He sees the pain, the loss of ability and the other effects that nerve-destroying conditions cause - and wishes he could give patients more effective treatments than what's available, or regenerate their nerves.

Then he heads to his research lab at the VA Ann Arbor Healthcare System, where his team is working toward that exact goal.

In new research published in several recent papers, Corey and his colleagues from the U-M Medical School, VAAAHS and the University of California, San Francisco report success in developing polymer nanofiber technologies for understanding how nerves form, why they don't reconnect after injury, and what can be done to prevent or slow damage.

Using polymer nanofibers thinner than human hairs as scaffolds, researchers coaxed a particular type of brain cell to wrap around nanofibers that mimic the shape and size of nerves found in the body.

They've even managed to encourage the process of myelination - the formation of a protective coating that guards larger nerve fibers from damage. They began to see multiple concentric layers of the protective substance called myelin start to form, just as they do in the body. Together with the laboratory team of their collaborator Jonah Chan at UCSF, the authors reported the findings in Nature Methods.

The research involves oligodendrocytes, which are the supporting actors to neurons - the "stars" of the central nervous system. Without oligodendrocytes, central nervous system neurons can't effectively transmit the electrical signals that control everything from muscle movement to brain function.

Oligodendrocytes are the type of cells typically affected by multiple sclerosis, and loss of myelin is a hallmark of that debilitating disease.

The researchers have also determined the optimum diameter for the nanofibers to support this process - giving important new clues to answer the question of why some nerves are myelinated and some aren't.

While they haven't yet created fully functioning "nerves in a dish," the researchers believe their work offers a new way to study nerves and test treatment possibilities. Corey, an assistant professor of neurology and biomedical engineering at the U-M Medical School and researcher in the VA Geriatrics Research, Education and Clinical Center, explains that the thin fibers are crucial for the success of the work.

"If it's about the same length and diameter as a neuron, the nerve cells follow it and their shape and location conform to it," he says. "Essentially, these fibers are the same size as a neuron."

More:
Stem cells and nanofibers stimulating nerve research

Posted in Stem Cells | Comments Off on Stem cells and nanofibers stimulating nerve research

Study of California Stem Agency Likely to be Released in About a Month

Posted: November 4, 2012 at 8:00 am


The $700,000, Institute of Medicine performance study of the $3 billion California stem cell agency is expected to be
released in late November or early December, the IOM said today.

In response to a question last week
from the California Stem Cell Report, Christine Stencel, senior media
relations officer for the IOM in Washington, D.C., briefly discussed
the release plans and the impact of the East Coast super-storm.
Here is the text of her response:

“The DC area escaped the worst of
Sandy’s thumping but nonetheless our schedules and planning have
been somewhat thrown off as we’re playing catch up after two days
of being shut down and some of our committee members and reviewers
are in the areas that got the brunt of the storm. We’re not sure
whether the storm will cause any delays in peer review, but we’re
working toward the goal of publicly releasing the report in late
November or early December. The study staff is working with committee
members to determine the best release format but I anticipate there
will be a press briefing. I’ll send a media advisory when we’ve
got all the details worked out.”

The stem cell agency is paying for the
report, which is examining the performance of the agency. The IOM
began its work in the summer of 2011.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iNEFrnWvUO0/study-of-california-stem-agency-likely.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Study of California Stem Agency Likely to be Released in About a Month

Geron Weighs Biotime Bid for hESC Biz

Posted: November 4, 2012 at 8:00 am


Geron, Inc., of Menlo Park, Ca., said
today it is assessing an offer by two of its former executives to buy
the human embryonic stem cell program that it abandoned nearly a year
ago.
Geron startled the stem cell world,
including the $3 billion California stem cell agency, when it
jettisoned the first clinical trial of an hESC therapy for financial
reasons. The agency had loaned the company $25 million just a few
months earlier. Geron repaid the loan with interest.
Geron has been mum until today about the Oct. 18 offer by Biotime, Inc., of Alameda, Ca., which is headed
by Michael West, who founded Geron in 1990. Tom Okarma, president of
Geron from 1999 to 2011, is involved with West on the deal and is now
working at Biotime.
Geron's remarks came during a
conference call on its third quarter earnings. A spokesman said the
company is working with Biotime to “assess the feasibility” of
the proposal. He said the proposed transaction is complex and the
company is seeking “additional important details.”
The spokesman declined to offer any
additional comments on the Biotime proposal when questioned following
his initial statement.  
See here and here for earlier stories on the California Stem Cell Report on the Biotime offer. 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/4JnJvoKwHpA/geron-weighs-biotime-bid-for-hesc-biz.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Geron Weighs Biotime Bid for hESC Biz

Biotime-Geron Deal Attracts Interest from Brit Investor

Posted: November 4, 2012 at 8:00 am


A British investment trust that has
invested in Geron says it is going to take an advantage of an offer
by an Alameda firm that is seeking to acquire Geron's human embryonic
stem cell assets.

Jonathan C. Woolf, managing director
of British & American Investment Trust PLC, said last week in a letter to its
shareholders that it is disappointed in Geron's performance and the abandonment of its hESC program last November. The sudden halt to the
program and its historic clinical trial also surprised the California
stem cell agency, which had loaned Geron $25 million just a few
months earlier. The agency has expressed an interest in continuing the trial.
Woolf said,

“We have been highly critical of
Geron management's decisions and strategy over the past 20 months, in
particular the decision in November 2011 to abruptly exit Geron's
regenerative medicine (stem cell) business in which it was the
acknowledged world leader. Since that time, Geron management has
attempted to sell or partner this business but to date has been
unable to announce any progress on this.”

Woolf's trust is not listed as a major
Geron shareholder by Morningstar, but Woolf said 17 percent of his firm's
investments are in the Menlo Park, Ca., company. The
specific size of the trust's holdings in Geron was not immediately
known.
Woolf pointed to the offer by Biotime,
Inc
., of Alameda, Ca., as a way for Geron shareholders to benefit. On
Oct. 18, Biotime proposed a complicated deal in which it would
acquire Geron's hESC program. Biotime's president, Michael West,
founded Geron in 1990. The head of the Biotime subsidiary that would acquire
the Geron assets is Tom Okarma, who was CEO of Geron from 1999 to 2011. (Here are links to brief stories on the offer: Fiercebiotech, New Scientist.)
In his letter, Woolf noted Geron's
declining stock performance. He said he is “seriously concerned”
that Geron has failed to find a buyer for the assets. Woolf said,

“These now dormant and untended
assets are inevitably losing value as competitors make progress in
Geron's absence from the field and patent protection periods
decline.”

Woolf continued,

“We believe BioTime's proposals would
make Geron's stem cell assets in combination with those of BioTime
once again the world's leading stem cell business with sufficient
resources to recommence the discontinued programmes and develop the
business further into the medium term.”

Woolf urged Geron directors and other
Geron shareholders to work with Biotime to complete the deal. Geron
has not commented on the offer.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/va_Yea0dbF8/biotime-geron-deal-attracts-interest.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Biotime-Geron Deal Attracts Interest from Brit Investor

Study of California Stem Agency Likely to be Released in About a Month

Posted: November 4, 2012 at 7:59 am


The $700,000, Institute of Medicine performance study of the $3 billion California stem cell agency is expected to be
released in late November or early December, the IOM said today.

In response to a question last week
from the California Stem Cell Report, Christine Stencel, senior media
relations officer for the IOM in Washington, D.C., briefly discussed
the release plans and the impact of the East Coast super-storm.
Here is the text of her response:

“The DC area escaped the worst of
Sandy’s thumping but nonetheless our schedules and planning have
been somewhat thrown off as we’re playing catch up after two days
of being shut down and some of our committee members and reviewers
are in the areas that got the brunt of the storm. We’re not sure
whether the storm will cause any delays in peer review, but we’re
working toward the goal of publicly releasing the report in late
November or early December. The study staff is working with committee
members to determine the best release format but I anticipate there
will be a press briefing. I’ll send a media advisory when we’ve
got all the details worked out.”

The stem cell agency is paying for the
report, which is examining the performance of the agency. The IOM
began its work in the summer of 2011.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iNEFrnWvUO0/study-of-california-stem-agency-likely.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Study of California Stem Agency Likely to be Released in About a Month

Geron Weighs Biotime Bid for hESC Biz

Posted: November 4, 2012 at 7:59 am


Geron, Inc., of Menlo Park, Ca., said
today it is assessing an offer by two of its former executives to buy
the human embryonic stem cell program that it abandoned nearly a year
ago.
Geron startled the stem cell world,
including the $3 billion California stem cell agency, when it
jettisoned the first clinical trial of an hESC therapy for financial
reasons. The agency had loaned the company $25 million just a few
months earlier. Geron repaid the loan with interest.
Geron has been mum until today about the Oct. 18 offer by Biotime, Inc., of Alameda, Ca., which is headed
by Michael West, who founded Geron in 1990. Tom Okarma, president of
Geron from 1999 to 2011, is involved with West on the deal and is now
working at Biotime.
Geron's remarks came during a
conference call on its third quarter earnings. A spokesman said the
company is working with Biotime to “assess the feasibility” of
the proposal. He said the proposed transaction is complex and the
company is seeking “additional important details.”
The spokesman declined to offer any
additional comments on the Biotime proposal when questioned following
his initial statement.  
See here and here for earlier stories on the California Stem Cell Report on the Biotime offer. 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/4JnJvoKwHpA/geron-weighs-biotime-bid-for-hesc-biz.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Geron Weighs Biotime Bid for hESC Biz

Biotime-Geron Deal Attracts Interest from Brit Investor

Posted: November 4, 2012 at 7:59 am


A British investment trust that has
invested in Geron says it is going to take an advantage of an offer
by an Alameda firm that is seeking to acquire Geron's human embryonic
stem cell assets.

Jonathan C. Woolf, managing director
of British & American Investment Trust PLC, said last week in a letter to its
shareholders that it is disappointed in Geron's performance and the abandonment of its hESC program last November. The sudden halt to the
program and its historic clinical trial also surprised the California
stem cell agency, which had loaned Geron $25 million just a few
months earlier. The agency has expressed an interest in continuing the trial.
Woolf said,

“We have been highly critical of
Geron management's decisions and strategy over the past 20 months, in
particular the decision in November 2011 to abruptly exit Geron's
regenerative medicine (stem cell) business in which it was the
acknowledged world leader. Since that time, Geron management has
attempted to sell or partner this business but to date has been
unable to announce any progress on this.”

Woolf's trust is not listed as a major
Geron shareholder by Morningstar, but Woolf said 17 percent of his firm's
investments are in the Menlo Park, Ca., company. The
specific size of the trust's holdings in Geron was not immediately
known.
Woolf pointed to the offer by Biotime,
Inc
., of Alameda, Ca., as a way for Geron shareholders to benefit. On
Oct. 18, Biotime proposed a complicated deal in which it would
acquire Geron's hESC program. Biotime's president, Michael West,
founded Geron in 1990. The head of the Biotime subsidiary that would acquire
the Geron assets is Tom Okarma, who was CEO of Geron from 1999 to 2011. (Here are links to brief stories on the offer: Fiercebiotech, New Scientist.)
In his letter, Woolf noted Geron's
declining stock performance. He said he is “seriously concerned”
that Geron has failed to find a buyer for the assets. Woolf said,

“These now dormant and untended
assets are inevitably losing value as competitors make progress in
Geron's absence from the field and patent protection periods
decline.”

Woolf continued,

“We believe BioTime's proposals would
make Geron's stem cell assets in combination with those of BioTime
once again the world's leading stem cell business with sufficient
resources to recommence the discontinued programmes and develop the
business further into the medium term.”

Woolf urged Geron directors and other
Geron shareholders to work with Biotime to complete the deal. Geron
has not commented on the offer.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/va_Yea0dbF8/biotime-geron-deal-attracts-interest.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Biotime-Geron Deal Attracts Interest from Brit Investor

stem cells | Now That You Saved Your Cord Blood, What Are You Going to Do With It? – Video

Posted: November 3, 2012 at 8:51 pm


stem cells | Now That You Saved Your Cord Blood, What Are You Going to Do With It?
http://www.cordbloodrecommendation.com The other two sources are bone marrow and peripheral (circulating) blood. ""There is much debate over whether to opt for a public or private cord blood bank. Considering the level of expertise needed for the entire process, you usually have to hire the services of private cord blood storage facilities. You are strongly recommended to do your math thoroughly. ""Cord blood is the material that stays in the umbilical cord and placenta after giving birth. It is important to get this blood fifteen minutes after birth, as it may not be viable later on. You #39;ve probably heard about the mystical power of stem cells. Currently, these cells are best known for being the best treatment of leukemia. She was in the advanced stages of Parkinson and was looking for treatment options. When the unit containing cord blood cells is processed, a cyropreservant is added to it. First year fees in the United States will typically be somewhere between $1700 and $2300. So, day-by-day man is trying to reach the ultimate knowledge. Even if a lot of people think that extracting stem cells from human embryos is unethical, those stem cells can also be extracted from umbilical cord blood which can be seen as less of a problem and is certainly something more ethical as well. 6. Patients who have received a bone marrow transplant are more likely to reject the new addition, which could lead to life threatening situations. Pros And ConsAdvantages - Let us first look at the ...From:HotelesEnBuenosAiresViews:0 0ratingsTime:01:31More inTravel Events

Originally posted here:
stem cells | Now That You Saved Your Cord Blood, What Are You Going to Do With It? - Video

Posted in Stem Cells | Comments Off on stem cells | Now That You Saved Your Cord Blood, What Are You Going to Do With It? – Video

cord blood banking cost | Benefits Of Cord Blood Banking – Video

Posted: November 3, 2012 at 8:51 pm


cord blood banking cost | Benefits Of Cord Blood Banking
http://www.cordbloodrecommendation.com Is cord blood banking free?Unfortunately, you cannot save your baby #39;s blood free of cost. As a matter of fact, it has stem cells which are very beneficial for some disorder treatments. Another method is to use a bag, where the umbilical cord is elevated and blood is drained out. The procedure involved transplanting blood from 2 cords, so that one of them could save her life. ""Cord Blood Storage is often described as a good investment or a type of insurance for your child in case he or she may need some type of cord blood transplantation in the future. You may be worried that the cost of tissue banking is going to be very expensive, but the truth is that it is a lot cheaper than you probably realize. An inspiring case is that of siblings Ashley and Kelvin J. With the advancement of stem cell research, there is likely to be more uses for cord blood in the future. Another benefit you can take is that it has low risk of contamination for it is collected from pregnant mother who has lower risk of blood-borne diseases and viruses. This is process is now known by the medical community as Placenta-Cord banking. ""Cord Blood also called ""placental blood,"" is the blood that remains in the umbilical cord and placenta after the cord has been cut following the birth of the baby. How much blood is required for this?The cord blood banking representative and the doctors try to collect as much blood as possible from the umbilical cord. Degenerative ...From:Alexander santafeViews:0 0ratingsTime:01:31More inTravel Events

Read more here:
cord blood banking cost | Benefits Of Cord Blood Banking - Video

Posted in Stem Cells | Comments Off on cord blood banking cost | Benefits Of Cord Blood Banking – Video

Page 254«..1020..253254255256..260270..»